November 22, 2026
Navigating the GLP-1 Fiscal Challenge Balancing Immediate Costs with Long-Term Health Outcomes in Employer-Sponsored Insurance

Navigating the GLP-1 Fiscal Challenge Balancing Immediate Costs with Long-Term Health Outcomes in Employer-Sponsored Insurance

The rapid proliferation of glucagon-like peptide-1 (GLP-1) receptor agonists has fundamentally altered the landscape of employer-sponsored healthcare, creating a complex financial dilemma for plan sponsors and trustees. According to a 2026 Business Group on Health survey, nearly 80% of employers reported that the inclusion of GLP-1 medications is driving healthcare expenditures significantly higher. While more than half of these organizations anticipate substantial clinical benefits from weight-management therapies, a notable disconnect has emerged: few see tangible evidence of these benefits within their aggregate insurance claims. This discrepancy is primarily attributed to a measurement problem rooted in timing. Total healthcare claims encompass both immediate pharmacy spending and delayed medical savings. Because the costs of these medications are realized instantly while the mitigation of chronic disease takes years to manifest, traditional accounting methods often make successful health programs appear to be failing.

The Evolution and Chronology of the GLP-1 Market

The current fiscal pressure is the culmination of a decade-long shift in metabolic pharmacology. While GLP-1 drugs were originally developed to manage Type 2 diabetes—with the FDA approving Exenatide as early as 2005—the trajectory changed significantly in 2017 with the approval of Ozempic (semaglutide). The subsequent 2021 approval of Wegovy specifically for chronic weight management triggered a surge in demand that has yet to plateau.

By 2023 and 2024, off-label use and high consumer demand led to widespread shortages and a massive increase in pharmacy benefit expenditures. Entering 2025, the impact became undeniable in the data. Multi-employer and public plans reported that GLP-1s for weight loss accounted for an average of 14.7% of total annual claims, while corporate plans saw an average of 11.4%. As the market moves toward 2027, Mercer actuaries estimate that rising GLP-1 utilization will account for a full percentage point of the projected growth in total health benefit costs. This chronology illustrates a rapid transition from a niche diabetic treatment to a primary driver of domestic healthcare inflation.

Distorting Year-over-Year Financial Results

The sheer scale of GLP-1 spending has reached a critical mass where it distorts the broader picture of population health management. When a single class of drugs accounts for more than 10% of total claims, its growth trajectory dictates the direction of the entire plan’s budget. For trustees and financial officers who focus primarily on the "bottom line," the rising cost curve can be misleading. A plan might successfully reduce emergency room visits, improve cardiovascular outcomes, or lower hospital readmission rates through diligent care management, yet these victories are often masked by the sheer volume of GLP-1 pharmacy invoices.

To accurately judge whether a healthcare program is functioning as intended, analysts argue that GLP-1 spending must be "normalized." This involves evaluating claims data through two distinct lenses. First, the total spending must be reviewed to determine overall plan solvency and to inform contribution decisions. Second, the incremental impact of GLP-1 spending should be isolated to allow for an independent evaluation of medical utilization and underlying cost trends. By separating these variables, trustees can identify the underlying value of their care management initiatives, even when rising pharmaceutical expenditures temporarily offset measurable savings in other categories.

The Divergence of the Cost and Benefit Curves

A primary challenge in justifying GLP-1 coverage is the temporal gap between the pharmacy invoice and the clinical "dividend." Research conducted by Aon, which tracked medical and pharmacy claims for more than 192,000 GLP-1 users between 2022 and 2025, provides a data-driven look at this lag. The study found that medical costs for GLP-1 users grew more slowly than those of matched non-users, but these improvements were not instantaneous.

For members utilizing the drugs to treat Type 2 diabetes, the growth in medical costs was six percentage points lower than the control group, but this difference only became statistically significant at the 30-month mark. For those using the drugs specifically for weight loss, a three-point reduction in cost growth was observed after 18 months. Because these improvements materialize well after the first year of treatment, a fund that evaluates the return on investment (ROI) at the 12-month mark will only see the high cost of the medication without the corresponding slowdown in medical utilization.

This lag creates a unique hurdle for corporate employers. As noted by Mercer, factors such as slow disease progression and high employee turnover often make the immediate ROI uncertain for private companies. If an employee starts a GLP-1 regimen but leaves the company after 12 months, the employer has paid for the expensive treatment while the future savings—reduced risk of heart attack, stroke, or orthopedic surgery—accrue to a future insurer. However, multi-employer health funds and public plans often operate on a different timeline. Members in these funds tend to remain covered for much longer periods, sometimes spanning decades. In these scenarios, the fund paying for the initial therapy is the same entity that will eventually benefit from the long-term reduction in chronic disease complications.

When GLP-1 Costs Mask the Value of Care Management

Adherence as the Primary Barrier to Investment Return

The financial viability of GLP-1 coverage is heavily dependent on medication adherence, which remains a significant hurdle. Data from Prime Therapeutics, cited by Mercer, reveals a concerning trend: only one in 12 members remains on a GLP-1 regimen for obesity after three years. This high rate of discontinuation represents a "leaky bucket" for health funds. If a member utilizes an expensive GLP-1 for six months and then stops, they likely incur the high cost of the drug without achieving the long-term weight loss or metabolic stabilization necessary to drive medical savings.

The Aon data reinforces the importance of persistence. Users who maintained at least 80% adherence saw much more dramatic reductions in medical cost growth—nine percentage points for diabetes patients and seven percentage points for weight-loss patients. This data suggests that the "investment" in GLP-1s only yields a "return" if the patient remains compliant with the therapy. Consequently, coverage approval is not the end of the process, but rather the beginning of a clinical management challenge.

The Role of Nurse-Led Care Management

To protect the financial investment in GLP-1s, many health plans are turning to nurse-led care management programs. These programs are designed to coordinate the clinical and practical aspects of therapy, addressing the reasons why members often discontinue treatment. Common side effects, such as gastrointestinal distress, are a leading cause of early cessation.

Nurses play a critical role in educating members on proper administration, managing side effects, and coordinating with providers to adjust dosages. If a member does stop using the medication, a care manager can assess the underlying reasons and alert the provider to look for alternative solutions, such as different formulations or lifestyle interventions. This level of coordination is intended to support adherence, thereby protecting the member’s health and ensuring the fund achieves the expected reduction in long-term medical utilization.

Measuring What GLP-1 Spending Obscures

To gain a comprehensive understanding of plan performance, trustees are encouraged to look beyond the total claims figure. In the first year of a GLP-1 program, the focus should shift toward "leading indicators" of health. These include:

  • Emergency Department (ED) Visits: Tracking the number of ED visits per 1,000 members.
  • Avoidable Hospitalizations: Measuring hospital stays that could have been prevented with better outpatient management.
  • Medication Adherence (PDC): Monitoring the "Proportion of Days Covered" for members on GLP-1 therapies to ensure they are following the prescribed regimen.

As the program matures, these metrics should expand to include "lagging indicators" such as the frequency of major adverse cardiovascular events (MACE) and the incidence of diabetes-related complications. By evaluating these clinical outcomes alongside pharmacy spending, trustees can form a more complete picture of whether their healthcare strategy is delivering value, even if the total spend continues to rise.

Fact-Based Analysis of Implications

The rise of GLP-1s is forcing a shift in how healthcare "value" is defined. Historically, pharmacy benefits were often managed as a siloed cost center, with the goal of minimizing drug spend through rebates and formularies. However, the high cost and high potential impact of GLP-1s require an integrated view of pharmacy and medical spending.

If funds fail to separate GLP-1 costs for analytical purposes, they risk making reactionary decisions—such as cutting coverage for effective care management programs—based on a misunderstood "bottom line." Conversely, by isolating these costs, trustees can maintain a clear view of broader healthcare trends. This approach allows for a more nuanced decision-making process: balancing the immediate fiscal pressure of rising pharmaceutical costs with the undeniable long-term health interests of the membership.

The broader implication for the insurance industry is a move toward "value-based" pharmacy management. This involves not just paying for a pill, but investing in a clinical pathway that includes coaching, monitoring, and long-term support. For health funds that can navigate the current "cost distortion" and maintain a focus on adherence and clinical outcomes, GLP-1s represent a powerful tool for reducing the long-term burden of chronic disease. For those who focus solely on the short-term pharmacy bill, these drugs will likely remain a source of significant financial frustration.

Leave a Reply

Your email address will not be published. Required fields are marked *